Iranian Red Crescent Medical Journal

Published by: Kowsar

Correlation of Body Mass Index and Serum Parameters With Ultrasonographic Grade of Fatty Change in Non-alcoholic Fatty Liver Disease

Ghobad Abangah 1 , Atefeh Yousefi 2 , Rouhangiz Asadollahi 3 , Yousef Veisani 4 , Paria Rahimifar 2 and Sajjad Alizadeh 2 , *
Authors Information
1 Department of Gastroenterology and Hepatology, Ilam University of Medical Sciences, Ilam, IR Iran
2 Student Research Committee, Ilam University of Medical Sciences, Ilam, IR Iran
3 Department of Pathology, Ilam University of Medical Sciences, Ilam, IR Iran
4 Department of Clinical Epidemiology, Ilam University of Medical Sciences, Ilam, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: January 5, 2014, 16 (1); e12669
  • Published Online: January 5, 2014
  • Article Type: Research Article
  • Received: June 2, 2013
  • Revised: August 31, 2013
  • Accepted: June 29, 2013
  • DOI: 10.5812/ircmj.12669

To Cite: Abangah G, Yousefi A, Asadollahi R, Veisani Y, Rahimifar P, et al. Correlation of Body Mass Index and Serum Parameters With Ultrasonographic Grade of Fatty Change in Non-alcoholic Fatty Liver Disease, Iran Red Crescent Med J. 2014 ; 16(1):e12669. doi: 10.5812/ircmj.12669.

Copyright © 2014, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008; 28(4): 339-50[DOI][PubMed]
  • 2. Fan JG, Peng YD. Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies. Hepatobiliary Pancreat Dis Int. 2007; 6(6): 572-8[PubMed]
  • 3. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond). 2008; 115(5): 141-50[DOI][PubMed]
  • 4. Choudhury J, Sanyal AJ. Clinical aspects of fatty liver disease. Semin Liver Dis. 2004; 24(4): 349-62[DOI][PubMed]
  • 5. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16): 1221-31[DOI][PubMed]
  • 6. Mavrogiannaki AN, Migdalis IN. Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data. Int J Endocrinol. 2013; 2013: 450639[DOI][PubMed]
  • 7. Qian Y, Fan JG. Obesity, fatty liver and liver cancer. Hepatobiliary Pancreat Dis Int. 2005; 4(2): 173-7[PubMed]
  • 8. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116(6): 1413-9[PubMed]
  • 9. Jamali R, Pourshams A, Amini S, Deyhim MR, Rezvan H, Malekzadeh R. The upper normal limit of serum alanine aminotransferase in Golestan Province, northeast Iran. Arch Iran Med. 2008; 11(6): 602-7[PubMed]
  • 10. Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol. 2012; 27(10): 1555-60[DOI][PubMed]
  • 11. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010; 28(1): 155-61[DOI][PubMed]
  • 12. Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol. 2007; 6(3): 161-3[PubMed]
  • 13. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003; 124(1): 71-9[DOI][PubMed]
  • 14. Rocha R, Cotrim HP, Carvalho FM, Siqueira AC, Braga H, Freitas LA. Body mass index and waist circumference in non-alcoholic fatty liver disease. J Hum Nutr Diet. 2005; 18(5): 365-70[DOI][PubMed]
  • 15. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Maccioni D, et al. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol. 2003; 18(5): 588-94[PubMed]
  • 16. Sanyal AJ, American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(5): 1705-25[PubMed]
  • 17. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(3): 745-50[PubMed]
  • 18. Kennedy Gillian. Non-alcoholic fatty liver disease: Can ultrasound assist in early diagnosis of prediabetes and delay progression to type2 diabetes mellitus. Sound Effects. 2009;
  • 19. American Gastroenterological Association. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(5): 1702-4[PubMed]
  • 20. Di Lelio A, Cestari C, Lomazzi A, Beretta L. Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology. 1989; 172(2): 389-92[DOI][PubMed]
  • 21. Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol. 1998; 11(6): 560-5[PubMed]
  • 22. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001; 21(1): 3-16[PubMed]
  • 23. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med. 1997; 126(2): 137-45[PubMed]
  • 24. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol. 2003; 15(5): 539-43[DOI][PubMed]
  • 25. Souza MR, Diniz Mde F, Medeiros-Filho JE, Araujo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol. 2012; 49(1): 89-96[PubMed]
  • 26. Sogabe M, Okahisa T, Tsujigami K, Fukuno H, Hibino S, Yamanoi A. Visceral fat predominance is associated with non-alcoholic fatty liver disease in Japanese women with metabolic syndrome. Hepatol Res. 2013; [DOI][PubMed]
  • 27. Lin YC, Chou SC, Huang PT, Chiou HY. Risk factors and predictors of non-alcoholic fatty liver disease in Taiwan. Ann Hepatol. 2011; 10(2): 125-32[PubMed]
  • 28. Ye J, Chen Z, Wang T, Tong J, Li X, Jiang J, et al. Role of tissue disorder markers in the evaluation of disease progress and outcome prediction: a prospective cohort study in non-cardiac critically ill patients. J Clin Lab Anal. 2010; 24(6): 376-84[DOI][PubMed]
  • 29. Purnak T, Beyazit Y, Ozaslan E, Efe C, Hayretci M. The evaluation of bone mineral density in patients with nonalcoholic fatty liver disease. Wien Klin Wochenschr. 2012; 124(15-16): 526-31[DOI][PubMed]
  • 30. Kotronen A, Yki-Jarvinen H, Mannisto S, Saarikoski L, Korpi-Hyovalti E, Oksa H, et al. Non-alcoholic and alcoholic fatty liver disease - two diseases of affluence associated with the metabolic syndrome and type 2 diabetes: the FIN-D2D survey. BMC Public Health. 2010; 10: 237[DOI][PubMed]
  • 31. Razavizade M, Jamali R, Arj A, Talari H. Serum parameters predict the severity of ultrasonographic findings in non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2012; 11(5): 513-20[PubMed]
  • 32. Obesity epidemic puts millions at risk from related diseases. WHO Press Release. 1997; 46: 12
  • 33. Kundrotas LW, Clement DJ. Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors. Dig Dis Sci. 1993; 38(12): 2145-50[PubMed]
  • 34. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992; 85(1): 37-45[PubMed]
  • 35. National Cholesterol Education Program Expert Panel on Detection Evaluation, Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25): 3143-421[PubMed]
  • 36. American Diabetes Association. Standards of medical care in diabetes--2010. Diabetes Care. 2010; 33 Suppl 1-61[DOI][PubMed]
  • 37. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26(11): 3160-7[PubMed]
  • 38. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995; 22(6): 1714-9[PubMed]
  • 39. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004; 40(4): 820-6[DOI][PubMed]
  • 40. Miksztowicz V, Lucero D, Zago V, Cacciagiu L, Lopez G, Gonzalez Ballerga E, et al. Hepatic lipase activity is increased in non-alcoholic fatty liver disease beyond insulin resistance. Diabetes Metab Res Rev. 2012; 28(6): 535-41[DOI][PubMed]
  • 41. Novakovic T, Inic Kostic B, Milinic S, Jovicevic L, Dzeletovic G. [Cardiovascular disease risk factors in patients with non-alcoholic fatty liver disease]. Med Pregl. 2013; 66(1-2): 24-31[PubMed]
  • 42. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009; 29(1): 113-9[DOI][PubMed]
  • 43. Oh SY, Cho YK, Kang MS, Yoo TW, Park JH, Kim HJ, et al. The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism. 2006; 55(12): 1604-9[DOI][PubMed]
  • 44. Rafeey M, Mortazavi F, Mogaddasi N, Robabeh G, Ghaffari S, Hasani A. Fatty liver in children. Ther Clin Risk Manag. 2009; 5(2): 371-4[PubMed]
  • 45. Thomopoulos KC, Arvaniti V, Tsamantas AC, Dimitropoulou D, Gogos CA, Siagris D, et al. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol. 2006; 18(3): 233-7[PubMed]
  • 46. Nakhjavani M, Khalilzadeh O, Khajeali L, Esteghamati A, Morteza A, Jamali A, et al. Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol. Lipids. 2010; 45(4): 321-7[DOI][PubMed]
  • 47. Lee SS, Park SH, Kim HJ, Kim SY, Kim MY, Kim DY, et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol. 2010; 52(4): 579-85[DOI][PubMed]
  • 48. Tarantino G, Conca P, Riccio A, Tarantino M, Di Minno MN, Chianese D, et al. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? J Transl Med. 2008; 6: 72[DOI][PubMed]
  • 49. Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012; 2012: 145754[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments